Factive Gets May User Fee Date For Community Acquired Pneumonia Label Expansion
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA accepts Oscient’s submission as a “complete response” to a Sept. 21 “approvable” letter for the antibiotic.